Business
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, today announced new findings on golidocitinib, a first-in-class Janus kinase 1 (JAK1) only inhibitor, in combination with PD-1 antibodies for patients who have progressed on anti-PD-1 therapy. The details of the trial design and clinical results will be presented at the 2025 European Lung Cancer Congress (ELCC 2025) in Paris, March 26-29.
About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A
[{"type":"list","items":[{"val":[{"type":"text","content":"Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC","length":117,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":213,"olType":false},{"type":"text","content":"SHANGHAI, March 20, 2025 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, today announced new findings on golidocitinib, a first-in-class Janus kinase 1 (JAK1) only inhibitor, in combination with PD-1 antibodies for patients who have progressed on anti-PD-1 therapy. The details of the trial design and clinical results will be presented at the 2025 European Lung Cancer Congress (ELCC 2025) in Paris, March 26-29.","length":531,"tagName":"p"},{"type":"image","alt":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","displaySize":"","headline":null,"caption":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":153,"url":"https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1u.Z_bHAhdSc0SaTeDpFdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd","width":400,"height":153}},"href":"https://mma.prnewswire.com/media/2084187/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Recent studies showed that the dysregulated activation of the JAK/STAT pathway, which leads to the prolonged release of IFN-γ, is a significant contributor to the resistance to immune checkpoint inhibitors in cancer immunotherapy. Preclinical and clinical studies have demonstrated that the combination of JAK inhibitors with PD-1 immunotherapy can reverse or delay onset of immunotherapy resistance by modulating the JAK/STAT pathway in Hodgkin's lymphoma and NSCLC. Golidocitinib has shown excellent clinical benefits by effectively inhibiting the JAK/STAT pathway, leading to its approval for the treatment of relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) in China. Preclin...
More updates from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A